🔗 Share this article

Former Prime Minister Rishi Sunak has intensified his campaign for a focused testing initiative for prostate gland cancer.

During a recently conducted conversation, he stated being "convinced of the urgency" of introducing such a system that would be affordable, achievable and "save countless lives".

His comments come as the British Screening Authority reevaluates its ruling from the previous five-year period against recommending routine screening.

News sources indicate the authority may uphold its current stance.

Athlete Contributes Voice to Campaign

Gold medal cyclist Sir Hoy, who has advanced prostate gland cancer, wants younger men to be screened.

He proposes decreasing the eligibility age for requesting a PSA blood screening.

Currently, it is not standard practice to asymptomatic males who are below fifty.

The PSA examination is debated however. Readings can increase for factors apart from cancer, such as infections, leading to misleading readings.

Opponents maintain this can result in unnecessary treatment and side effects.

Targeted Screening Initiative

The suggested screening programme would concentrate on men aged 45–69 with a hereditary background of prostate gland cancer and African-Caribbean males, who encounter twice the likelihood.

This group comprises around 1.3 million men in the Britain.

Charity estimates suggest the system would cost twenty-five million pounds per year - or about £18 per person per individual - comparable to intestinal and breast examination.

The estimate includes 20% of eligible men would be invited each year, with a seventy-two percent response rate.

Medical testing (imaging and biopsies) would need to rise by almost a quarter, with only a modest increase in NHS staffing, according to the report.

Medical Community Response

Several medical experts are doubtful about the value of testing.

They assert there is still a risk that patients will be intervened for the cancer when it is not strictly necessary and will then have to experience complications such as incontinence and sexual performance issues.

One respected urological professional remarked that "The issue is we can often identify conditions that doesn't need to be addressed and we potentially create harm...and my concern at the moment is that risk to reward ratio requires refinement."

Patient Perspectives

Patient voices are also influencing the discussion.

A particular instance involves a sixty-six year old who, after requesting a PSA test, was detected with the cancer at the time of 59 and was informed it had spread to his pelvis.

He has since experienced chemical therapy, radiation treatment and hormone treatment but is not curable.

The patient endorses testing for those who are at higher risk.

"That is very important to me because of my sons – they are 38 and 40 – I want them screened as soon as possible. If I had been screened at fifty I am confident I wouldn't be in the situation I am currently," he said.

Future Actions

The Screening Advisory Body will have to weigh up the data and arguments.

While the latest analysis suggests the ramifications for workforce and availability of a testing initiative would be achievable, opposing voices have maintained that it would take imaging resources away from individuals being treated for other conditions.

The ongoing discussion underscores the complex trade-off between timely diagnosis and possible excessive intervention in prostate gland cancer management.